Vaccine: X · Published 2026-05-09 · DOI 10.1016/j.jvacx.2026.100827
Cervical cancer is one of the most common types of cancer worldwide, which is mainly caused by the human papillomavirus (HPV). Vaccines against HPV are available, inducing a strong humoral response against some, but not all, of the high-risk HPV types. Therefore, it is important that vaccines with a broader spectrum of protection against all high-risk HPVs are developed. Thus, this study aimed to develop a multi-epitope vaccine based on CD8 T-cell epitopes that have been shown to be immunogenic for broad-spectrum cell-mediated immunity against high-risk HPVs. The antigen was constructed by joining the epitopes with linkers and adjuvants. In silico cloning of the multi-epitope vaccine was performed, and its stability and functionality were validated by molecular docking simulations. The vaccine was observed to be stable, non-allergenic, presenting a potential antigenicity score and strong binding to TLR4, indicating its viability as a vaccine against HPV, both for therapeutic and prophylactic purposes.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →